Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BMEA | Common Stock | Purchase | $12M | +400K | +12.61% | $30.00 | 3.57M | Mar 30, 2023 | See Footnotes | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | BMEA | Stock Option (right to buy) | 28.9K | Mar 30, 2023 | Common Stock | 28.9K | $17.00 | Direct | F3, F4 | |||||
holding | BMEA | Stock Option (right to buy) | 23.9K | Mar 30, 2023 | Common Stock | 23.9K | $10.20 | Direct | F4, F5 |
Id | Content |
---|---|
F1 | Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. |
F2 | Represents (i) 1,795,928 shares of Common Stock held by the Master Fund, (ii) 1,717,232 shares of Common Stock held by Fund III, and (iii) 57,712 shares of Common Stock held by the Account. |
F3 | The options were granted with a 36 month vesting period, vesting monthly. |
F4 | Stock options granted to Bihua Chen, in her capacity as a director of the Issuer. |
F5 | The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant. |